Exchange: NASDAQ·Updated 07:17 PM EDT
NBIX logo

NBIXNeurocrine Biosciences, Inc.

$171.00
$2.06
(1.18%)
Today
Closed $172.04
$1.04
(0.60%)
After Hours
EarningsJul 30
Mkt Cap$17.51B
Vol1.05M
News
all
press releases
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
News Placeholder
More News
News Placeholder
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus
DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.
Zacks
News Placeholder
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Zacks
News Placeholder
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
Zacks
News Placeholder
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Zacks
News Placeholder
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 9, 2026 Conference Call and Webcast Scheduled for Thursday, July...
PR Newswire
News Placeholder
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
Zacks
News Placeholder
Agilent Strengthens Biopharma Growth Prospects With AI Expansion
A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.
Zacks
News Placeholder
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
News Placeholder
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.
Zacks
<
1
2
...
>

Advertisement|Remove ads.